New Member Orientation

Our primary responsibility as IRB reviewers is to work to safeguard the rights and welfare of research participants. 

     1. Regulatory and Ethical Basis

  • 45CFR46 (the Common Rule and Subparts B-D)
  • OHRP and FDA • Regulations are viewed as the "the floor"
  • Federal-wide assurances (FWAs)
  • Reporting obligations and oversight

      2. Structure-Activity Relationships

  • The convened IRB is the vested authority
  • IRB staff vs. members roles are distinct
  • Members, alternates, and quorum obligations
  • Minutes

 

  1. Confidentiality

          • Confidentiality of review protects the integrity of the review process

          • We are obligated to respect an investigator's protocol as proprietary information/intellectual property

 

      2. Conflict of interest

          • The IRB must be and must be perceived to be fair and impartial, immune from pressure by the institution's administration, the investigators whose protocols are brought before it, or other....sources." (OHRP guidebook)

          • No IRB may have a member participate in the IRB's initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB (45CFR46.107)

 

  1. Levels of IRB Review

    • Full-board review is the default process

    • Only Minimal Risk research that falls within predefined categories and minor changes to approved research can be expedited

    • Federal rules Exempt some research: NOT AT PI

     

  2. Steps in Review

    • Level of review is assigned   

    • Protocol Management   

    • Chair or member review 

    • Subcommittee Review

       – Primary and secondary reviewers 

       – Grant, Sponsor Materials

       – PSF 

       – Communication with PI's

    • Full Board Review

    • The idea of "Simple Concurrence"

    • Final approval

    • Changes to approved research

    • Continuing Review

    • Unanticipated problems, Adverse events, monitoring data, and protocol violations

       – CFs

       – Communication with Chair

     

  3. The regs: 45CFR46: Definitions

    • Research - a systematic investigation designed to develop or contribute to generalizable knowledge.

    Human Subject - a living individual about whom an investigator conducting research obtains

       – data through intervention or interaction with the individual, or

       – identifiable private information

    §46.116 General requirements for informed consent.

        ....no investigator may involve a human being as a subject in research covered by this policy unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative.

And so:

       ....if it is defined as research

       ....and it involves human subjects, 

       ....then IRB review  and informed consent are required.

Minimal Risk

   • Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research [as experienced by the subjects of the study] are not greater in and of themselves than those ordinarily encountered in daily life [for an average person] or during the performance of routine physical or psychological examinations or tests.

Expedited Review

   (b) An IRB may use the expedited review procedure to review either or both of the following:

   (1) some or all of the research appearing on the list and found by the reviewer(s) to involve no more than minimal risk,

   (2) minor changes in previously approved research during the period (of one year or less) for which approval is authorized.

 

  1. Criteria for IRB approval

    (1)Risks to subjects are minimized:

        (i) by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, and

        (ii) whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.

    Identifying Risks

    • Consider the nature of the disorder and inherent risks

    • Consider the phase of illness under study

    • Carefully consider co-morbidities and contraindications

    • Consider duration of delay to treatment

    • Consider permitted/restricted treatments

    • Consider the setting

    Minimizing Risks (cont'd)

    • Examine inclusion criteria

    • Examine exclusion criteria 

    • Examine frequency and nature of assessments

    • Consider qualifications of staff

    • Require operationalized clinical drop-out criteria to permit otherwise un-approvable research

    • Request feedback and research monitoring

    • Require (suggest?) end of study care/referral

    (2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be  expected to result.

    (3) Selection of subjects is equitable.

    The IRB should be particularly cognizant of the special problems of research involving vulnerable populations...

    Protections in the risk-benefit analysis

    • Weighing autonomy vs. protectionism

    • Tensions between risk reduction and scientific aims.

    • Defining unacceptable risk.

    • What is the precedent?

    ....Consider the scientific benefits and the risks introduced by the research:

    are the risks only those necessary to answer the proposed scientific question?

     

         Vulnerable Populations

         Some persons are in need of extensive protection, even to the point of excluding them from activities which may             harm them;

         other persons require little protection beyond making sure they undertake activities freely and with awareness  of  possible adverse consequence.

                                                                                                                                                               

          Implications and Applications

          • Vulnerability is multi-dimensional, and occurs along a spectrum--not simply as present or absent.

          • Protections are proportional to the degree of vulnerability.

          • Protections are proportional to the degree of risk and benefit.

 

         Protections in subject selection, and recruitment

         • Study the least vulnerable population that will serve the project’s scientific aims.

         • Study less vulnerable groups first.

         • Address stigma and burden.

         • Protection begin in approaches to advertising, screening, and recruitment.

         • Carefully consider compensation.

 

         Fundamental Protections

         • IRB review and informed consent represent two fundamental protections.

         • The protections provided by consent do not relieve the IRB of its obligation to determine what is approvable,                   what is "reasonable." 

         • Yet, these are not wholly independent considerations

 

irb review

       (4) Informed consent will be sought from each prospective subject or the subject's legally authorized representative

       (5) Informed consent will be appropriately documented

       (6) When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.

       (7) When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the                         confidentiality of data.

       (8) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children,               prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged                       persons, additional safeguards have been included in the study to protect the rights and welfare of these                     subjects.

       Risk/Benefit Thresholds: Adults vs. Children

                                                                    From Subpart A, criteria for study approval

        • Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result.

                                                                    Versus, from Subpart D (Children)

        • The risk is justified by the anticipated benefits to the subjects, and

        • The relation of the anticipated benefit to the risk presented by the study is at least as favorable to the subjects as that provided by available alternative approaches.

Types of Research

Requirements        

Not greater than minimal risk

 

Greater than minimal risk and prospect of direct benefit

 

 

 

Greater than minimal risk and NO prospect of direct benefi

 

 

 

 

 

 

 

Any other research

 

 

 

 

 

 

(1)Assent of child and permission of at least one parent

 

(1)Assent of child and permission of at least one parent

(2) Anticipated benefit justifies the risk

(3) Benefit/risk ratio is at least as favorable as that of alternative approaches

 

(1) Assent of child and permission of at least one parent

(2) Only a minor increase over minimal risk

(3) Likely to yield generalizable knowledge about the child's disorder or condition that is of vital importance for the understanding or the amelioration of the disorder or condition

(4) The intervention or procedure presents experiences to the child that are reasonably commensurate with those in the child's actual or expected medical, dental, psychological, social, or educational situations.

 

(2) IRB finds that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children

• Assent of child and permission of both parents

(3) The HHS Secretary approves, after consultation with a panel of experts in pertinent disciplines (e.g., science, medicine, education, ethics, law) and following publication in the Federal Register and public comment

  1. Protections, consent and capacity to consent

    • Informed, Understanding, Voluntary

    • Investigators are responsible for ascertaining that the subject has comprehended the information

    • When the risks are more serious, that obligation increases.

    The nature of decisional "vulnerability"

    • Situational vs. disorder-related  impairment

      (e.g. emergency room, "institutions" vs. stroke)

    • Global vs. specific impairment

      (e.g. sedative overdose vs. paranoid psychosis)

    • Static vs. progressive vs. episodic vs. time limited impairment

      (e.g. severe mental retardation vs. Alzheimer's disease vs. manic depressive disorder vs. TBI)

    • Acute vs. persistent impairment

      (e.g. hypoxia secondary to asthma or acute pain vs. MR, autism)

    Information

          • The research procedure                                                     

          • The purpose of the study

          • The risk of harm or discomfort

          • The anticipated benefits

          • The alternatives to study participation

          • The opportunity to ask questions

          • Statement about study withdrawal

          Capacity is task specific

 

capacity task specific

 

IRB Waiver of Consent

The IRB may approve a waiver of some or all of the consent requirements provided that:

    • The research involves no more than minimal risk to subjects;

    • The waiver will not adversely affect the rights and welfare of subjects;

    • The research could not practicably be carried out without the waiver; and

    • Whenever, appropriate, the subjects will be debriefed.

Waiver of documentation of Consent

The IRB may waive the requirement for documentation of consent in cases where:

    • The principle risks are those associated with a breach of confidentiality concerning the subject's participation in the research; and the consent document is the only record linking the subject with the research;

OR

    • The research presents no more than minimal risk; and involves procedures that do not require written consent when performed outside of a research setting.

  1. Confidentiality

    • Identification (the mere fact of linking them to involvement in the study) of subjects and/or their responses could place them at risk of criminal or civil liability or be damaging to the subjects'

      financial standing, employability, insurability, reputation, or be stigmatizing

    • There is no researcher-patient "privilege"

    • Our obligations and the quid pro quo

  2. Resources and references

          • Belmont Report

          • The Regs

          • IRB Member Handbook

          • LW Roberts (2 papers)

          • http://www.hhs.gov/ohrp/ 

          • IRB

          • Workshops, conferences

       4. Indemnification

  • You are covered